Customer Appreciation Sale.
15% off with promo code "APPRECIATION2023" on check out or purchase order

ABT-737

Catalog No.: A10255

Bcl-2 Inhibitor

ABT-737

ABT-737 Chemical Structure

CAS NO. 852808-04-9

ABT-737 is a pan-Bcl-2 inhibitor. IC50 values ranged from 192 nM (the pre-B cell line Hal-01) to <10 μM (Nalm-6, K562 and HL-60).

Availability: In stock

Package Price Qty
5 mg
$50.00
10 mg
$90.00
50 mg
$300.00
100 mg
$480.00
10mM * 1mL in DMSO
$80.00
Custom Size Get quote

Free Overnight Delivery on orders over $500

Next day delivery by 10:00 a.m. Order now.

Warning Products are for laboratory research use only. Not for human use. We do not sell to patients.
  • Jung Mo Lee, .et al. ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model, Yonsei Med J, 2022, Jan;63(1):16-25 PMID: 34913280
  • AidaVarela-Moreira, .et al. Utilizing in vitro drug release assays to predict in vivo drug retention in micelles, Int J Pharm, 2022, Apr 25;618:121638 PMID: 35257802
  • Daniel F R Boehmer, .et al. OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis, Sci Immunol, 2021, Jul 16;6(61) PMID: 34272227
  • Shivani Arora, .et al. Invariant natural killer T cells coordinate removal of senescent cells, Med, 2021, 2,1-13
  • Ying Ji, .et al. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment, Nat Commun, 2020, Aug 25;11(1):4249 PMID: 32843618
  • Birgit Ritschka, .et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice, Genes Dev, 2020, Apr 1;34(7-8):489-494 PMID: 32139422
  • Hiroki Akiyama, .et al. Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically With BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells, Cancers, 2020, 12 (2) PMID: 32050632
  • Hsu CC, .et al. α7-Nicotine acetylcholine receptor mediated nicotine induced cell survival and cisplatin resistance in oral cancer, Arch Oral Biol, 2020, Mar;111:104653 PMID: 31935534
  • Gupta VK, .et al. Lysophosphatidic acid promotes survival of T lymphoma cells by altering apoptosis and glucose metabolism, Apoptosis, 2020, Feb;25(1-2):135-150 PMID: 31867678
  • Meikle V, .et al. A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 2018, Nov 12. pii: AAC.01846-18 PMID: 30420480
  • Chauhan D, .et al. BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1β Maturation in Macrophages, Cell Rep, 2018, Nov 27;25(9):2354-2368.e5 PMID: 30485805
  • Jose Mario Gonzalez-Meljem, .et al. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma, Nat Commun, 2017, 8: 1819 PMID: 29180744
  • Zhang C, .et al. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response, J Biol Chem, 2017, Sep 8;292(36):15105-15120 PMID: 28673964
  • Eun Young Kim, .et al. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer, Neoplasia, 2017, Apr; 19(4): 354-363 PMID: 28319809
  • Masayoshi Toge, .et al. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer, Int J Oncol., 2015, Apr;46(4):1844-8 PMID: 25647738

Biological Activity

ABT-737 is a pan-Bcl-2 inhibitor. IC50 values ranged from 192 nM (the pre-B cell line Hal-01) to <10 μM (Nalm-6, K562 and HL-60).
Targets
Target Value
Bcl-2EC50:30.3nM
Bcl-xLEC50:78.7nM
Bcl-wEC50:197.8nM
Bcl-BEC50:1.82 uM
Bfl-1EC50>10 uM
Mcl-1EC50>10 uM
In vitro (25°C) DMSO 92 mg/mL (113.1 mM)
Water Insoluble
Ethanol Insoluble
In vivo 2%DMSO+40%PEG300+5%Tween80+53%ddH2O 1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 12.29 mL 61.47 mL 122.94 mL
0.5 mM 2.46 mL 12.29 mL 24.59 mL
1 mM 1.23 mL 6.15 mL 12.29 mL
5 mM 0.25 mL 1.23 mL 2.46 mL

*The above data is based on the productmolecular weight 813.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Catalog Num A10255
Actions Inhibitor
CAS No. 852808-04-9
Formula C42H45ClN6O5S2
M. Wt 813.4
Purity >98%
SMILES CN(C)CC[[email protected]](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
Storage

Store lyophilized at -20ºC, keep desiccated.
In lyophilized form, the chemical is stable for 36 months.
In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Tags

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

Product Questions

Product Questions

No Questions
You may also be interested in the following product(s)
Keywords:buy ABT-737 | ABT-737 Supplier | purchase | cost | manufacturer | order | distributor | buy 852808-04-9| 852808-04-9 Supplier | purchase 852808-04-9 | 852808-04-9 cost | 852808-04-9 manufacturer | order 852808-04-9 | 852808-04-9 distributor
Rewards